25724648|t|Specific amyloid beta clearance by a catalytic antibody construct.
25724648|a|Classical immunization methods do not generate catalytic antibodies (catabodies), but recent findings suggest that the innate antibody repertoire is a rich catabody source. We describe the specificity and amyloid beta (Abeta)-clearing effect of a catabody construct engineered from innate immunity principles. The catabody recognized the Abeta C terminus noncovalently and hydrolyzed Abeta rapidly, with no reactivity to the Abeta precursor protein, transthyretin amyloid aggregates, or irrelevant proteins containing the catabody-sensitive Abeta dipeptide unit. The catabody dissolved preformed Abeta aggregates and inhibited Abeta aggregation more potently than an Abeta-binding IgG. Intravenous catabody treatment reduced brain Abeta deposits in a mouse Alzheimer disease model without inducing microgliosis or microhemorrhages. Specific Abeta hydrolysis appears to be an innate immune function that could be applied for therapeutic Abeta removal. 
25724648	223	231	catabody	Chemical	-
25724648	286	291	Abeta	Gene	11820
25724648	314	322	catabody	Chemical	-
25724648	381	389	catabody	Chemical	-
25724648	405	410	Abeta	Gene	11820
25724648	451	456	Abeta	Gene	11820
25724648	492	497	Abeta	Gene	11820
25724648	589	597	catabody	Chemical	-
25724648	608	613	Abeta	Gene	11820
25724648	614	623	dipeptide	Chemical	MESH:D004151
25724648	634	642	catabody	Chemical	-
25724648	663	668	Abeta	Gene	11820
25724648	694	699	Abeta	Gene	11820
25724648	734	739	Abeta	Gene	11820
25724648	765	773	catabody	Chemical	-
25724648	798	803	Abeta	Gene	11820
25724648	818	823	mouse	Species	10090
25724648	824	841	Alzheimer disease	Disease	MESH:D000544
25724648	865	877	microgliosis	Disease	
25724648	908	913	Abeta	Gene	11820
25724648	1003	1008	Abeta	Gene	11820
25724648	Association	MESH:D000544	11820

